Mirtazapin Aurobindo (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonises postsynaptic 5‑HT2, 5‑HT3 and H1 receptors, enhancing serotonergic activity while producing sedative effects that contribute to its antidepressant action.

The appropriate dose of Mirtazapin Aurobindo is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments may be required for special populations, and patients should follow the prescriber’s instructions exactly.

Mirtazapin Aurobindo is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used only if the potential benefit justifies any possible risk to the fetus, and breastfeeding decisions should be made in consultation with a healthcare professional.

To order Mirtazapin Aurobindo, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in stronger sedative and appetite‑stimulating effects. It may be preferred when patients experience insomnia or weight loss, but the choice of therapy should be individualized based on efficacy, side‑effect tolerance and comorbid conditions.

Mirtazapin Aurobindo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Mirtazapin Aurobindo is taken orally, usually once daily in the evening to take advantage of its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, seizures, and the emergence or worsening of suicidal thoughts, especially during the early phase of treatment. Patients should be monitored closely for signs of infection, convulsions, or any change in mood or behavior, and seek immediate medical attention if these occur.

Mirtazapin Aurobindo should be avoided in patients with known hypersensitivity to mirtazapine or any of its excipients, and in individuals currently taking monoamine oxidase inhibitors (MAOIs) unless a wash‑out period of at least 14 days has been observed. Caution is also advised for patients with severe hepatic impairment.